Parkinson’s Disease

104 results.

July 27, 2016 Indicators of Parkinson’s disease risk found in unexpected places

GRAND RAPIDS, Mich. (July 27, 2016)—Clues that point toward new risk mechanisms for developing Parkinson’s disease are hiding in some unusual spots, according to

VAI DEFAULT HEADER
July 12, 2016 Michael J. Fox Foundation, Van Andel Research Institute and The Cure Parkinson’s Trust collaborate to assess the clinical use and development of nilotinib in Parkinson’s disease

Note: To read the commentary published in the Journal of Parkinson's Disease click here. Investigators will focus on safety for long-term use in non-cancer…

June 14, 2016 Lessons from lactose intolerance: Investigating epigenomic aging

New insights into lactose intolerance may give scientists more than a better understanding of why some people lose the ability to digest…

May 24, 2016 Explaining the epigenome: An interview with Dr. Viviane Labrie (part two)

Dr. Viviane Labrie is an assistant professor in Van Andel Research Institute’s Center for Neurodegenerative Science. Her area of expertise is the…

May 17, 2016 Explaining the epigenome: An interview with Dr. Viviane Labrie (part one)

Dr. Viviane Labrie is an assistant professor in Van Andel Research Institute’s Center for Neurodegenerative Science. Her area of expertise is the…

April 4, 2016 Changing the course: Parkinson’s disease research in 2016

By Patrik Brundin, M.D., Ph.D. Director, Center for Neurodegenerative Science The time has come to shift the paradigm on Parkinson’s disease. Never before have we…

April 4, 2016 Infographic: Seven Parkinson's terms to know

Parkinson’s is a progressive disease caused by the abnormal clumping of a protein in brain cells, some of which produce a chemical called dopamine that…

VAI DEFAULT HEADER
February 22, 2016 Promising respiratory drug focus of new clinical trial for Parkinson’s disease

GRAND RAPIDS, Mich. (February 22, 2016)—A medication approved to treat various respiratory diseases and that has demonstrated neuroprotective effects in preclinical studies is the focus…